{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-025104","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.284310+00:00","generated_at":"2026-05-17T10:49:49.513742+00:00","sec_items":["1.01","1.02","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan","bullets":["Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.","Chairman Dr. Huh purchased $1,250,000 principal note for $1,000,000, paying $162,567 cash and cancelling $837,433 Peak Bio loan.","Extended expiration of Series A Warrants on 1,973,211 ADSs by 48 months from original expiry.","Paid Paulson Investment Company a 5% advisory fee ($70K) on ~$1.4M gross cash proceeds.","Notes are unsecured; proceeds used for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-025104","json":"https://secwatch.observer/filing/0001641172-25-025104.json","markdown":"https://secwatch.observer/filing/0001641172-25-025104.md","text":"https://secwatch.observer/filing/0001641172-25-025104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000164117225025104/0001641172-25-025104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000164117225025104/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:49:49.513742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"220074ce083700a3fa0740eab11919d7668566a0","claim":"Akari Therapeutics Plc incurred debt of $2,826,250 maturing 12-month anniversary of the respective Closing Dates.","evidence_excerpt":"the Company completed its first tranche of closings of the Offering and issued Notes with an aggregate purchase price of $2,261,000 and an aggregate principal amount of $2,826,250","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000164117225025104/0001641172-25-025104-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"$2,826,250"},{"label":"Maturity","value":"12-month anniversary of the respective Closing Dates"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}